Method of identifying risk of cancer and therapeutic options
There is provided a method of identifying risk of cancer in a human subject, the method comprising: determining in a biological sample of the subject, whether a copy number amplification of at least one continuous genomic region specific to human chromosome 1q21 is present, wherein the presence of a copy number amplification of the region specific to human chromosome 1q21 represents an elevated risk of cancer in the subject and the at least one continuous genomic region is selected from the group consisting of: a human TUFT 1 gene or a gene from the human S100 family. It is also provided a method of treating cancer in a subject determined to have a copy number amplification of a region specific to human chromosome 1q21, the method comprising administering a therapeutic agent capable of suppressing IRAK1, IRAK4 or a S100 family member, such as Pacritinib. There are also provided a method of treating cancer, related polynucleotides, kits, therapeutic agents and use of the therapeutic agents.
1. A method of treating breast cancer in a subject, the method comprising:
determining that a copy number amplification of a region specific to human chromosome 1q21.3 is present in a tumour tissue and/or blood sample from the subject,
wherein determining that a copy number amplification of a region specific to human chromosome 1q21.3 is present in a tumour tissue and/or blood sample from the subject comprises evaluating a copy number ratio of at least one continuous genomic region located on human chromosome 1q21.3 in the subject to a reference continuous genomic region in the subject, wherein if the copy number ratio exceeds a threshold value it is indicative of copy number amplification, and
wherein the at least one continuous genomic region selected from the group consisting of: a human TUFT1 gene, a gene from the human S100 family, and combinations thereof,
administering to the subject pacritinib or therapeutically effective analogs thereof,
wherein the pacritinib or therapeutically effective analogs thereof leads to a reduction in the expression of a human S100 family gene driving breast cancer progression in the subject,
wherein the human S100 family gene is selected from S100A7, S100A8, S100A9 and combinations thereof.
2. The method of claim 1 , wherein the subject was previously ineffectively treated for breast cancer by an earlier therapy, wherein the earlier therapy does not comprise administration of pacritinib or therapeutically effective analogs thereof.
3. The method of claim 1 , wherein the blood sample comprises cell-free DNA.
4. The method of claim 1 , wherein the threshold value is obtained by establishing the copy number ratio of the at least one continuous genomic region in a healthy subject to the reference continuous genomic region in the healthy subject.
5. The method of claim 1 , wherein said evaluating the copy number ratio of the at least one continuous genomic region comprises evaluating an average copy number ratio of at least two continuous genomic regions located on human chromosome 1q21.3 and wherein said average copy number comprises:
obtaining the copy number ratio of each of the at least two continuous genomic regions; and
averaging the copy number ratios of the at least two continuous genomic regions to obtain the average copy number ratio.
6. The method of claim 1 , wherein the threshold value is obtained by evaluating a mean copy number ratio of the at least one continuous genomic region located on human chromosome 1q21.3 based on two or more healthy reference subjects and wherein said evaluating the mean copy number ratio based on two or more healthy reference subjects comprises:
evaluating the copy number ratio of the at least one continuous genomic region of a first healthy reference subject;
evaluating the copy number ratio of the at least one continuous genomic region of a second healthy reference subject; and
adding the copy number ratios of the two or more healthy reference subjects; and
dividing by the number of healthy reference subjects.
7. The method of claim 1 , wherein said evaluating the copy number ratio of the at least one continuous genomic region comprises evaluating a copy number ratio of the at least one continuous genomic region of one or more subsequent healthy reference subjects to obtain one or more subsequent copy number ratios.
8. The method of claim 1 , wherein said determining whether a copy number amplification of a region specific to human chromosome 1q21.3 is present in the tumour tissue/blood sample from the subject comprises contacting the tumour tissue/blood sample with one or more oligonucleotides for hybridizing to the region specific to human chromosome 1q21.3.
9. The method of claim 8 , wherein the one or more oligonucleotides comprises a primer for amplifying the at least one continuous genomic region located on human chromosome 1q21.3.
10. The method of claim 8 , wherein the one or more oligonucleotides comprise a sequence selected from the group consisting of:
(SEQ ID NO. 1)
TTTTAATCAGAGGGTGAGGGTGAT;
(SEQ ID No. 2)
GCTTCTCAATGTTGGAGGATACA;
(SEQ ID No. 3)
GTCAAGATTGAGGAGGAAGAAGC;
(SEQ ID No. 4)
TTCATAGATGGCTATGCCTCGG;
(SEQ ID No. 5)
GGTGTTTCCCCACTAGCCA;
(SEQ ID No. 6)
CCCAGAGAGTGTATTGGCCC;
(SEQ ID No. 7)
TGCTATGTGGCCTTGGACAGATCACC;
(SEQ ID No. 8)
AGTTTAAAGATCTCAGAGAGAGCCGAGGCA;
(SEQ ID No. 9)
CCTTAGCGTATCACATGTGGACATGGACA;
and combinations thereof.
11. The method of claim 1 , wherein said determining step has a sensitivity of no less than 85% and a specificity of no less than 85% in detecting a copy number amplification of a region specific to human chromosome 1q21.3.